alexa
Reach Us +44-1235425476
Patient Selection Factors for Stereotactic Body Radiotherapy and Radioembolization for Hepatic Metastases | OMICS International | Abstract
ISSN: 2155-9619

Journal of Nuclear Medicine & Radiation Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Patient Selection Factors for Stereotactic Body Radiotherapy and Radioembolization for Hepatic Metastases

TE Schefter*

Department of Radiation Oncology, University of Colorado School of Medicine, 1665 Aurora Ct, Suite 1032 MS F-706, Aurora, CO 80045, USA

Corresponding Author:
TE Schefter
Department of Radiation Oncology
University of Colorado School of Medicine1665 Aurora Ct
Suite 1032 MS F-706, Aurora, CO 80045, USA
Tel: 720-848-0116
Fax: 720-848-0239
E-mail: Tracey. [email protected]

Received Date: June 28, 2011; Accepted Date: December 04, 2011; Published Date: December 06, 2011

Citation: Schefter TE (2011) Patient Selection Factors for Stereotactic Body Radiotherapy and Radioembolization for Hepatic Metastases. J Nucl Med Radiat Ther 2:119. doi: 10.4172/2155-9619.1000119

Copyright: © 2011 Schefter TE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Liver metastases are a common source of morbidity and mortality. Despite significant improvements in outcome with systemic therapy in recent years, it is infrequent that liver metastases or sites of macrometastatic disease are controlled permanently. Furthermore, most liver metastases are not amenable to what is considered the gold standard locally ablative therapy, surgical resection and consequently there has been a surge in interest in non surgical ablative therapies. Review of patient selection factors for two such liver directed radiation therapies, radioembolization and stereotactic body radiation therapy (SBRT) will be addressed.

Recommended Conferences

Clinical Oncology & Radiation Therapy

Singapore, Singapore
Share This Page
Top